Lysostaphin: model for a specific enzymatic approach to infectious disease.
D000818:Animals; D001433:Bacteriolysis / Q000187:drug effects; D003030:Coagulase; D004285:Dogs; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D006801:Humans; D007928:Lethal Dose 50; D008248:Lysostaphin / Q000096:biosynthesis / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D051379:Mice; D008826:Microbial Sensitivity Tests; D009668:Nose Diseases / Q000188:drug therapy / Q000276:immunology; D010068:Oxacillin / Q000494:pharmacology; D010400:Penicillin G / Q000494:pharmacology; D010403:Penicillin Resistance; D011817:Rabbits; D051381:Rats; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000276:immunology; D013210:Staphylococcus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D013204:Staphylococcus Phages / Q000187:drug effects
D003030:Coagulase; D008248:Lysostaphin; D010400:Penicillin G; D010068:Oxacillin